Skip to Main Content

After three years of squabbling, Bristol Myers Squibb has agreed to pay up to $11 million to settle a lawsuit that accused several drugmakers of conspiring to block generic competition to HIV medicines.

The lawsuit described an unusual scheme concerning fixed-dose combinations of different HIV medicines, which have been widely used for several years to combat the virus. The complaint also cited Gilead Sciences and Johnson & Johnson, whose medicines are useful components in these combinations, which are sometimes referred to as cocktail treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment